BTIG Reiterates Buy on Bicara Therapeutics, Maintains $39 Price Target
BTIG analyst Jeet Mukherjee reiterates Bicara Therapeutics (NASDAQ:BCAX) with a Buy and maintains $39 price target.
Share
Why It Matters
An expert investor analyst still thinks Bicara is a good company to own. They believe the stock could be worth about $39 per share.
This read is generated by AI from raw market data and is for education only. It is not financial advice, not a signal, and not a recommendation to buy or sell.
Tickers in Play
Last session drawn · prints held ~15 minutes · licensed exchange data
Source: Benzinga · Read the original report at the publisher. Headline and figures shown for context; data may be delayed.
Disclosure: Educational and informational purposes only. Not financial advice. We educate, not advise. Market data may be delayed up to 15 minutes unless marked real-time. Past performance is not indicative of future results.